Enter Note Done

Go to previous page in this tab

Session

Heart Failure and Cardiomyopathies
1091 - Heart Failure and Cardiomyopathies 04

Schedule

Notes

Credits

South Hall

Sess#: 1091

Set Timezone

Timezone

Generic 'disconnected' Message

Location: South Hall

Session Type: Poster Contributions

Credit Type - CME: 0; CNE: 0; CNErx: 0; CPE: 0; Dual CME/ABIM MOC: 0; Dual CME/ABP MOC: 0; PA: 0; IPCE: 0; ASRT: 0

[Board 129] A META-ANALYSIS OF REAL-WORLD DATA TO EVALUATE THE CARDIOVASCULAR OUTCOMES WITH EMPAGLIFLOZIN VERSUS DAPAGLIFLOZIN IN PATIENTS WITH TYPE-2 DIABETES - Caleb Carver

[Board 130] ARE ANTI-TNF MEDICATIONS RELATED TO HEART FAILURE? A STUDY OF THE FAERS DATABASE - Yousef Al-Mabrouk

[Board 131] ENHANCING THE INITIATION AND OPTIMIZATION OF GUIDELINE-DIRECTED MEDICAL THERAPY (GDMT) IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION (HFREF): A PLAN-DO-CHECK-ACT CYCLE-2 STUDY - William Lim

[Board 132] IMPACT OF TAFAMIDIS ON ECHOCARDIOGRAPHIC PARAMETERS IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS - Mustafa Shehzad

[Board 133] IN SILICO COMPARISON OF MAVACAMTEN DOSING AND TITRATION WITH OR WITHOUT PROSPECTIVE CYP2C19 GENOTYPING - Samira Merali

[Board 134] IN SILICO ANALYSIS PREDICTS SIMILAR SAFETY PROFILES FOR BI-ANNUAL AND QUARTERLY ECHOCARDIOGRAM MONITORING IN PATIENTS ON A STABLE DOSE OF MAVACAMTEN - Samira Merali

[Board 135] MYOSIN INHIBITION FOR LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY RESISTANT TO PREVIOUS ADVANCED THERAPY - Elizabeth Adlestein

[Board 136] ALL-CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES WITH TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES AND HEART FAILURE WITH REDUCED EJECTION FRACTION - Aravinthan Vignarajah

[Board 137] LONG-TERM FAVORABLE CARDIAC REMODELING IN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS TREATED WITH MAVACAMTEN FOR UP TO 128 WEEKS: INSIGHTS FROM VALOR-HCM TRIAL - Milind Y. Desai

[Board 138] HYDROCHLOROTHIAZIDE VERSUS METOLAZONE IN DIURETIC RESISTANT ACUTE DECOMPENSATED HEART FAILURE - A META-ANALYSIS - Dominic J. Vacca

[Board 139] EVALUATION OF CYTOCHROME P450 2C9, 2C19, AND 2D6 INHIBITION ON THE PHARMACOKINETICS OF AFICAMTEN IN HEALTHY PARTICIPANTS - Neha Maharao

[Board 140] INTERLEUKIN-1 INHIBITORS FOR RECURRENT PERICARDITIS: A MISSED OPPORTUNITY? - Sunaina Kalidindi

[Board 141] IMPACT OF BAROSTIM DEVICE ON GUIDELINE DIRECTED MEDICAL THERAPY FOR HEART FAILURE WITH REDUCED EJECTION FRACTION - Prutha Lavani

[Board 142] ACETAZOLAMIDE VERSUS THIAZIDES WITH LOOP DIURETICS IN ACUTE DECOMPENSATED HEART FAILURE - Allyson Chan

[Board 143] THE IMPACT OF ELECTRONIC HEALTH RECORD ALERTS AND PEER COMPARISON EMAILS ON THE PRESCRIBING RATES OF SGLT2 INHIBITORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS IN HF PATIENTS: PRELIMINARY RESULTS OF A RANDOMIZED TRIAL - Joshua Sethi

[Board 144] RELATIONSHIP OF PERICARDIAL FLUID CONTENT WITH OUTCOME IN PATIENTS UNDERGOING PERICARDIOCENTESIS - Aidan Kane

[Board 145] PROGNOSTIC IMPACT OF GERIATRIC SYNDROMES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION - Omar Zainul

[Board 146] ECHOCARDIOGRAPHIC AND DEMOGRAPHIC CHARACTERISTICS OF A POPULATION WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS (ATTR-CM) - Melanie Sun

[Board 173] ESTIMATING THE PLACEBO EFFECT OF PATIENT-REPORTED OUTCOMES IN SHAM-CONTROLLED DEVICE TRIALS: A SECONDARY ANALYSIS OF THE REDUCE LAP-HF II STUDY - Andrew Girard

[Board 174] EARLY DIAGNOSIS OF CARDIAC AMYLOIDOSIS IN PATIENTS PRESENTING WITH BILATERAL CARPAL TUNNEL SYNDROME - Yuliya Paulenka

[Board 175] RESIDUAL PULMONARY HYPERTENSION AND CLINICAL OUTCOMES IN ACUTE DECOMPENSATED HEART FAILURE PATIENTS STRATIFIED BY LEFT VENTRICULAR EJECTION FRACTION - Toshikazu D. Tanaka

[Board 176] URINE TUBULAR BIOMARKERS ARE ASSOCIATED WITH NATRIURESIS IN PATIENTS WITH ACUTE HEART FAILURE - Nicholas W. Wettersten

[Board 177] BIOMARKERS OF KIDNEY TUBULE AND CARDIAC HEALTH ARE NOT ASSOCIATED WITH CREATININE INCREASES IN ACUTE HEART FAILURE - Nicholas W. Wettersten

[Board 178] EXPLORING RISK FACTORS OF CARDIOVASCULAR EVENTS IN PATIENTS WITH DIFFERENT TYPES OF SYNDROMIC AND METABOLIC CARDIOMYOPATHY - Qing Yang

[Board 179] CHARACTERISTICS AND PREDICTORS OF CARDIAC OUTCOMES IN PATIENTS WITH SYNDROMIC AND METABOLIC CARDIOMYOPATHIES - Qing Yang

[Board 180] EFFECTIVENESS OF SEMAGLUTIDE FOR OBESITY MANAGEMENT IN HEART FAILURE WITH PRESERVED EJECTION FRACTION: A SYSTEMATIC REVIEW AND A META-ANALYSIS - Priya Hotwani

[Board 181] PREDICTING READMISSIONS IN ACUTE DECOMPENSATED HEART FAILURE PATIENTS USING ADMISSION TO DISCHARGE GFR CHANGES - Mehmet Gunduz

[Board 182] CLINICAL VALUE OF TISSUE DOPPLER DERIVED BIPHASIC PRE AND POST EJECTION VELOCITY SIGNALS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION - Alaa Omar

[Board 183] EFFICACY AND SAFETY OF DAPAGLIFLOZIN IN ACUTE HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS - Priya Hotwani

[Board 184] TEMPORAL CHANGES IN BIOMARKERS AND QUALITY OF LIFE PRIOR TO ADVERSE CLINICAL OUTCOMES IN HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION - Henri Lu

[Board 185] ASSOCIATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-7 AND HEART FAILURE: A SYSTEMIC REVIEW AND META-ANALYSIS - Zara Mobin

[Board 186] PORTAL VENOUS FLOW CONGESTION AND RENAL FUNCTION IN PATIENTS WITH ACUTE HEART FAILURE - Dmitry Shchekochikhin